News

Scientists have identified six proteins that could serve as targets for new treatments designed to slow multiple sclerosis (MS) progression. The data showed that one protein, RRM2B, may interact with the approved MS treatment Mavenclad (cladribine), while the other proteins interacted with molecules that are not currently used…

People with multiple sclerosis (MS) who were older than 60 had a low risk of disease flares whether they continued or stopped taking disease-modifying therapies (DMTs), according to a recent study. According to researchers, these data suggest that some older adults with MS may be able to consider…

For teenagers, eating a healthy diet during one’s adolescent years — particularly one rich in milk, cheese, and yogurt, among other dairy products — may help reduce the risk of developing late-onset multiple sclerosis (MS) later in life, a study has found. In fact, participants in the study who…

An autologous hematopoietic stem cell transplant (aHSCT) helped over 80% of people with multiple sclerosis (MS) remain free from disease activity for at least two years, a real-world study in Germany found. The strongest benefits were seen in people with relapsing-remitting MS (RRMS), with better outcomes observed in…

Two new research projects are looking at whether the hormonal and biological changes that happen around menopause play a role in how multiple sclerosis (MS) progresses in women, which could help doctors better predict the course of the disease and time treatments more effectively. “By better understanding the biological…

An artificial intelligence (AI) model that analyzes brain scans alongside clinical and demographic data showed high accuracy in predicting which people with multiple sclerosis (MS) were likely to experience cognitive decline over time, according to a new study. Using tools that show which parts of the data most influenced…

The number of people living with multiple sclerosis (MS) has risen steadily over the past two decades, but the increase appears to be driven largely by longer survival after diagnosis rather than by more people developing the disease. That’s according to findings of a large study that analyzed nationwide…

Imviva Biotech is cleared to launch a basket Phase 1b trial testing its investigational off-the-shelf CAR T-cell therapy CTA313 in progressive multiple sclerosis (MS) and other B-cell-mediated autoimmune diseases. The announcement follows the clearance of the company’s investigational new drug (IND) application by the U.S. Food and Drug…

Among people with clinically isolated syndrome (CIS) — an initial episode of symptoms suggestive of multiple sclerosis (MS) — lower levels of certain fatty molecules in the blood are associated with higher rates of future disease relapses, a new study found. Adding these metabolic features to established demographic…

A new study in mice shows that an advanced imaging technique called magnetic particle imaging, or MPI, can track exactly where therapeutic cells go after they are injected into the body. This approach could eventually help researchers and doctors study and optimize cell-based therapies for people with multiple sclerosis…

The approved injection therapy Kesimpta (ofatumumab) is generally safe and helps most adults with relapsing forms of multiple sclerosis (MS) keep their disease stable over time with few or no relapses, a real-world study has found. The data show treatment is especially effective when started at a younger…

Differences in gut bacteria may affect how people with multiple sclerosis (MS) respond to dietary interventions, according to a study. The researchers stressed that their analysis was limited to data from a small group of people, so further studies will be needed to validate and expand on the results.

The U.S. Food and Drug Administration (FDA) has placed a clinical hold on Quantum Biopharma’s application seeking clearance to begin a Phase 2 trial testing Lucid-MS in people with multiple sclerosis (MS). Quantum said the FDA requested further information before clearing the investigational new drug (IND) application and…

A new formulation of Briumvi (ublituximab) — TG Therapeutics’ therapy for relapsing forms of multiple sclerosis (MS) — designed for possible at-home self-injection was generally well tolerated and showed biological activity consistent with the approved intravenous (into-the-vein) version, according to Phase 1 trial data. The Phase 1 trial is…

First-line treatment with TG Therapeutics’ Briumvi (ublituximab) in clinical trials among people with relapsing forms of multiple sclerosis (MS) led to significantly fewer relapses, reduced signs of MRI disease activity, and better disability outcomes compared with those given the older drug Aubagio (teriflunomide) as their initial therapy.

The Multiple Sclerosis Association of America (MSAA) is expanding its patient-centered research network to include more than 1,000 people with multiple sclerosis (MS) receiving care at 20 sites across the U.S. Known as the Multiple Sclerosis Implementation Network (MSIN), the initiative brings together healthcare providers, researchers, people…

Higher consumption of ultra-processed foods, such as soft drinks, packaged snacks, and ready-to-eat meals, may be associated with an increased risk of developing multiple sclerosis (MS). That’s according to a large study involving nearly 186,000 middle-aged adults in the U.K., which found that each 10% increase in ultra-processed food intake…

A new report from the National MS Society reveals that despite major advances in treatments over the last few decades, people living with multiple sclerosis (MS) still face massive gaps in their care — particularly when it comes to managing crushing fatigue, stopping disease progression, and reversing nerve…

Kesimpta (ofatumumab) was more effective than Aubagio (teriflunomide) at suppressing disease activity in people with highly active, relapsing forms of multiple sclerosis (MS), according to new analyses from the Phase 3 ASCLEPIOS trials. After two years, those on Kesimpta were nearly 20 times more likely to achieve…

A new partnership aims to advance software that uses artificial intelligence (AI) to examine brain MRI scans for signs characteristic of multiple sclerosis (MS). Neurophet said it will work with the Vall d’Hebron Institut de Recerca (VHIR), the research institute of Vall d’Hebron University Hospital in Spain, to…

An app-based, one-to-one peer support program from Shift.ms that connects people newly diagnosed with multiple sclerosis (MS) with someone more experienced may help them feel more confident in managing their condition, with self-reported psychological benefits for both people in the pairing. That’s according to five-year data from the…

Abnormal fat buildup inside the brain’s immune cells may help to drive neurological damage and disability progression in people with progressive forms of multiple sclerosis (MS), a study found. The findings also point to a possible therapeutic target. Researchers showed that blocking an enzyme called MAGL may help reverse…

Three years of treatment with Sanofi’s investigational antibody therapy frexalimab was associated with persistently low disease activity and no new safety concerns in people with relapsing forms of multiple sclerosis (MS). That’s according to new data from an ongoing open-label extension phase of a global Phase…

Subjective, patient-reported data on lived experiences should always be considered in the care of chronic conditions like multiple sclerosis (MS), according to a recent presentation. In a survey, many people with MS reported feeling that their lived experiences aren’t given enough consideration during visits with their care providers, and…

The understanding and management of neuropsychiatric symptoms such as depression and cognitive difficulties in multiple sclerosis (MS) have advanced substantially, but there’s more progress to be made, said Anthony Feinstein, PhD, a neuropsychiatrist and professor of psychiatry at the University of Toronto. Feinstein, who delivered the June Halper Memorial Lecture…

Advocates around the globe are coming together this Saturday, May 30, for World MS Day to push for better care, earlier diagnoses, and increased awareness for people living with multiple sclerosis (MS). Launched in 2009 by the MS International Federation (MSIF), a coalition of MS advocacy groups,…

The Consortium of Multiple Sclerosis Centers (CMSC) 2026 annual meeting kicks off today in Charlotte, North Carolina, bringing together clinicians, researchers, rehabilitation specialists, and patient advocates for three days of discussions on the latest advances in multiple sclerosis (MS) care and research. At this year’s meeting, CMSC is…

Patient enrollment is complete in a Phase 2a clinical trial testing Tiziana Life Sciences‘ foralumab nasal spray in people with nonactive secondary progressive multiple sclerosis (SPMS), a form of multiple sclerosis (MS) with limited treatment options. “Reaching full enrollment in this landmark study is a testament to the strong…

Many women with multiple sclerosis (MS) have misconceptions or a lack of information about how the disease may affect pregnancy and childbirth, and healthcare providers rarely broach the topic, a study found. The findings suggest that women with MS may be making decisions about family planning based…

The neuroprotective effects of exercise in multiple sclerosis (MS) may be aided by the irisin hormone. A study showed irisin reduced nerve cell loss and eased clinical symptoms in a mouse model of the disease, making the hormone a potential new therapeutic target. And unlike existing MS therapies…